Ask AI
ProCE Banner Activity

Advances in Bispecific Antibody Therapy for Multiple Myeloma

Slideset

Download this slideset featuring the latest data and expert insights on the current and future use of bispecific antibodies in multiple myeloma. 

Released: June 11, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc

Target Audience

This activity has been designed to meet the educational needs of hematologists, oncologists, and other healthcare professionals who care for patients with multiple myeloma. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate emerging safety and efficacy data on new bispecific antibody therapies into the personalized treatment of patients with multiple myeloma 

  • Identify patients with multiple myeloma who may be eligible for ongoing clinical trials evaluating currently available and emerging bispecific antibodies

  • Manage and mitigate adverse events associated with bispecific antibody treatment in patients with multiple myeloma

  • Compare safety and efficacy profiles among available bispecific antibodies to individualize therapy selection for patients with relapsed/refractory multiple myeloma